Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
Key Highlights
- ➤Robert DiTota appointed Senior Strategic Advisor, Global Commercialization, effective September 15, 2026
- ➤Nexalin (NXL) begins commercialization strategy for DIFS™ platform across approved and target markets
- ➤Gen-2 SYNC approved in China, Brazil, Oman and Israel
- ➤Abbott neuromodulation division led by DiTota represented approximately $700 million in business
- ➤Nexalin (NXL) seeks distribution relationships and commercial infrastructure to convert approvals into sales
Expert Statements
Mark White, President and Chief Executive Officer of Nexalin Technology
“The clinical and regulatory work of the past several years is what makes this next phase possible”
Mark White, President and Chief Executive Officer of Nexalin Technology
“We have approvals in four countries and a growing body of published data behind the technology.”
Mark White, President and Chief Executive Officer of Nexalin Technology
“What we need to build now is the commercial organization that turns that into sales.”
Mark White, President and Chief Executive Officer of Nexalin Technology
“Rob has spent his career doing exactly that in neuromodulation, at Abbott and at Medtronic,in the United States.”
Mark White, President and Chief Executive Officer of Nexalin Technology
“He understands how these products reach physicians and patients, how distribution partners are selected and held accountable, and what has to be in place before a launch.”
Mark White, President and Chief Executive Officer of Nexalin Technology
“We are fortunate to have him working alongside us as we make this transition.”
Robert DiTota, Senior Strategic Advisor, Global Commercialization, Nexalin Technology
“Nexalin has established an important clinical and regulatory foundation.”
Robert DiTota, Senior Strategic Advisor, Global Commercialization, Nexalin Technology
“The company has generated controlled clinical data, published peer-reviewed results, and secured regulatory approvals for its Gen-2 SYNC device in four countries.”
Robert DiTota, Senior Strategic Advisor, Global Commercialization, Nexalin Technology
“The commercial opportunity now is to translate that foundation into disciplined market development in approved geographies while continuing to build the evidence, regulatory strategy and infrastructure needed for broader commercialization.”
Robert DiTota, Senior Strategic Advisor, Global Commercialization, Nexalin Technology
“That is the work in front of us.”
Appointment as Senior Strategic Advisor marks the Company’s expansion from clinical development toward commercialization of its DIFS™ platform in the United States, Europe and South America
DiTota spent over two decades in neuromodulation at Abbott and Medtronic, two of the largest companies in the field, including responsibility for Abbott’s North America commercial neuromodulation business, a division representing approximately $700 million in business
Get started
Create a free account to read the full story.